| Invokana (canagliflozin) / J&J, Daiichi Sankyo, Mitsubishi Tanabe |
ACTRN12610000194066: A Randomised Double-Blind Placebo-Controlled Multicenter Study with Extension to Evaluate the Efficacy Safety and Tolerability of Canagliflozin in the Treatment of Subjects with Type 2 Diabetes
Mellitus Who Have Moderate Renal Impairment |
|
|
| Not yet recruiting | 3 | 240 | | | Johnson& Johnson Pharmaceutical Research & Development, LLC, Johnson& Johnson Pharmaceutical Research & Development, LLC | Type 2 diabetes in patietns with moderate renal impairment. | | | | |
NCT03170518 / 2016-005223-88: A Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (>=10 to <18 Years) With Type 2 Diabetes Mellitus |
|
|
| Completed | 3 | 171 | Europe, US, RoW | Canagliflozin 100 mg, JNJ-28431754, Canagliflozin 300 mg, Placebo | Janssen Research & Development, LLC | Diabetes Mellitus, Type 2 | 09/23 | 09/23 | | |
NCT05364190: Canagliflozin in Patients With Acute Decompansted Heart Failure |
|
|
| Completed | 3 | 142 | RoW | Canagliflozin, Empagliflozin | October 6 University, Cairo University, National Heart Institute, Egypt | Chronic Heart Failure, Acute Heart Failure, Diabetes Mellitus | 09/23 | 12/23 | | |
| Not yet recruiting | 2/3 | 24 | Canada | Canagliflozin, Invokana, Placebo | Ottawa Heart Institute Research Corporation | Diabetes Type 2, Coronary Artery Disease | 12/25 | 12/25 | | |
